Patients who received 48 weeks of treatment (i.e., 44 weeks of boceprevir with PR after a 4-week PR lead-in period) achieved an SVR rate of 68% (Supporting Fig. 1). The side effects associated with the addition of boceprevir to PR include increased rates of dysgeusia, neutropenia, and anemia. Dysgeusia that is observed when boceprevir is added to the standard of care is usually mild and rarely,

if ever, requires the discontinuation of therapy. Although neutropenia may lead to infections in those receiving PR, severe infections Caspase activity are infrequent, and treatment cessation is rarely warranted. Anemia associated with triple therapy (PR and boceprevir) is primarily driven by ribavirin-related hemolytic anemia, which begins during the 4-week PR lead-in period and is responsible for the majority of the hemoglobin decline.11 Anemia associated with boceprevir typically contributes an additional decline LDK378 molecular weight of 1 g/dL to the decline associated with ribavirin therapy. Anemia associated with boceprevir is thought to be due to the bone marrow–suppressive effect of the drug, whereas anemia associated with ribavirin is attributed

to hemolysis. Similar to the development of anemia with PR therapy, the development of anemia with boceprevir-based treatment is associated with higher SVR rates.12 In the SPRINT-2 trial, dose modifications due to anemia were required almost twice as often for patients on boceprevir selleck regimens

versus the PR control groups (21% versus 13%). However, the rates of discontinuation due to adverse events were not significantly different for the patients on boceprevir-containing regimens (13%) and the PR controls (12%), and discontinuation due to anemia was rare as well (2% for the patients on boceprevir-containing regimens and 1% for the PR controls). It should be emphasized that erythropoietin supplementation was used in the trial. Drug interactions are significant with boceprevir and are discussed in the next section. Boceprevir is primarily metabolized by two pathways: the aldo-keto reductase pathway and the cytochrome P450 3A4 pathway. Importantly, it is a reversible inhibitor of cytochrome P450 3A4. All individuals who are candidates for boceprevir therapy require an assessment of drug-drug interactions (Supporting Table 1). Before therapy is started, thyroid-stimulating hormone levels must be determined, and pregnancy testing is required for women of child-bearing potential. Additionally, complete blood count monitoring should be performed before treatment initiation, at weeks 2, 4, 6, 8, and 12, and monthly thereafter.